197 related articles for article (PubMed ID: 25339847)
1. Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia.
Ellis JJ; Sadosky AB; Ten Eyck LL; Cappelleri JC; Brown CR; Suehs BT; Parsons B
Clinicoecon Outcomes Res; 2014; 6():389-99. PubMed ID: 25339847
[TBL] [Abstract][Full Text] [Related]
2. A retrospective, matched cohort study of potential drug-drug interaction prevalence and opioid utilization in a diabetic peripheral neuropathy population initiated on pregabalin or duloxetine.
Ellis JJ; Sadosky AB; Ten Eyck LL; Mudumby P; Cappelleri JC; Ndehi L; Suehs BT; Parsons B
BMC Health Serv Res; 2015 Apr; 15():159. PubMed ID: 25889173
[TBL] [Abstract][Full Text] [Related]
3. Potential drug-drug and drug-condition interactions among fibromyalgia patients initiating pregabalin or duloxetine: prevalence and health care expenditure impact.
Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL
Pain Med; 2014 Aug; 15(8):1282-93. PubMed ID: 24401017
[TBL] [Abstract][Full Text] [Related]
4. Real-world evaluation of health-care resource utilization and costs in employees with fibromyalgia treated with pregabalin or duloxetine.
Harnett J; Margolis J; Cao Z; Fowler R; Sanchez RJ; Mardekian J; Silverman SL
Pain Pract; 2011; 11(3):217-29. PubMed ID: 21199319
[TBL] [Abstract][Full Text] [Related]
5. Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine.
Johnston SS; Udall M; Cappelleri JC; Johnson BH; Shrady G; Chu BC; Silverman SL
Am J Health Syst Pharm; 2013 Dec; 70(24):2207-17. PubMed ID: 24296843
[TBL] [Abstract][Full Text] [Related]
6. Real-world comparison of health care utilization between duloxetine and pregabalin initiators with fibromyalgia.
Peng X; Sun P; Novick D; Andrews J; Sun S
J Pain Res; 2014; 7():37-46. PubMed ID: 24470771
[TBL] [Abstract][Full Text] [Related]
7. Health care costs in patients with fibromyalgia on pregabalin vs. duloxetine.
Burke JP; Sanchez RJ; Joshi AV; Cappelleri JC; Kulakodlu M; Halpern R
Pain Pract; 2012 Jan; 12(1):14-22. PubMed ID: 21615857
[TBL] [Abstract][Full Text] [Related]
8. Comparing common reasons for inpatient and outpatient visits between commercially-insured duloxetine or pregabalin initiators with fibromyalgia.
Zhao Y; Sun P; Bernauer M
J Pain Res; 2012; 5():443-51. PubMed ID: 23152695
[TBL] [Abstract][Full Text] [Related]
9. Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin, or pregabalin in fibromyalgia.
Kim SC; Landon JE; Lee YC
Arthritis Res Ther; 2015 Jan; 17(1):18. PubMed ID: 25627453
[TBL] [Abstract][Full Text] [Related]
10. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care.
Gore M; Tai KS; Chandran A; Zlateva G; Leslie D
J Med Econ; 2012; 15(1):19-31. PubMed ID: 21970699
[TBL] [Abstract][Full Text] [Related]
11. Direct medical costs and medication compliance among fibromyalgia patients: duloxetine initiators vs. pregabalin initiators.
Sun P; Peng X; Sun S; Novick D; Faries DE; Andrews JS; Wohlreich MM; Wu A
Pain Pract; 2014 Jan; 14(1):22-31. PubMed ID: 23489659
[TBL] [Abstract][Full Text] [Related]
12. Comparison of medication adherence and healthcare costs between duloxetine and pregabalin initiators among patients with fibromyalgia.
Zhao Y; Sun P; Watson P; Mitchell B; Swindle R
Pain Pract; 2011; 11(3):204-16. PubMed ID: 20807351
[TBL] [Abstract][Full Text] [Related]
13. Impact of a Novel Cost-Saving Pharmacy Program on Pregabalin Use and Health Care Costs.
Martin C; Odell K; Cappelleri JC; Bancroft T; Halpern R; Sadosky A
J Manag Care Spec Pharm; 2016 Feb; 22(2):132-44. PubMed ID: 27015252
[TBL] [Abstract][Full Text] [Related]
14. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.
Burke JP; Sanchez RJ; Joshi AV; Cappelleri JC; Kulakodlu M; Halpern R
Pain Pract; 2012 Mar; 12(3):209-18. PubMed ID: 21676163
[TBL] [Abstract][Full Text] [Related]
15. Healthcare Costs and Medication Adherence Among Patients with Fibromyalgia: Combination Medication vs. Duloxetine, Milnacipran, Venlafaxine, and Pregabalin Initiators.
Marlow NM; Simpson KN; Vaughn IA; Jo A; Zoller JS; Short EB
Pain Pract; 2018 Feb; 18(2):154-169. PubMed ID: 28419725
[TBL] [Abstract][Full Text] [Related]
16. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin.
Zhao Y; Sun P; Watson P
Curr Med Res Opin; 2011 Apr; 27(4):785-92. PubMed ID: 21303196
[TBL] [Abstract][Full Text] [Related]
17. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care.
Gore M; Zlateva G; Tai KS; Chandran AB; Leslie D
Pain Pract; 2011; 11(2):167-79. PubMed ID: 20723096
[TBL] [Abstract][Full Text] [Related]
18. Changes in opioid use and healthcare costs among U.S. patients with diabetic peripheral neuropathic pain treated with duloxetine compared with other therapies.
Zhao Y; Wu N; Chen S; Boulanger L; Police RL; Fraser K
Curr Med Res Opin; 2010 Sep; 26(9):2147-56. PubMed ID: 20662557
[TBL] [Abstract][Full Text] [Related]
19. Medication dosing patterns associated with duloxetine and pregabalin among patients with fibromyalgia.
Sun P; Zhao Y; Zhao Z; Watson P
Curr Med Res Opin; 2011 Sep; 27(9):1793-801. PubMed ID: 21810060
[TBL] [Abstract][Full Text] [Related]
20. Initial use of pregabalin, patterns of pain-related pharmacotherapy, and healthcare resource use among older patients with fibromyalgia.
Gore M; Sadosky A; Zlateva G; Clauw D
Am J Manag Care; 2010 May; 16(5 Suppl):S144-53. PubMed ID: 20586523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
